Accordingly, Yang et al. postulated that the delivery of exogenous PD-L1 and Gal-9 to β-cells might result in an immunosuppressive therapeutic effect, thereby alleviating T1D[30]. Here, LGALS9 is linked to type 1 diabetes mellitus.